Roche Q1 sales down on forex effects
Swiss drugmaker Roche said on Thursday that its first-quarter sales declined because of negative foreign exchange effects but rose at constant exchange rates.
Roche Holding AG (RHHBY) Shareholder/Analyst Call Transcript
Roche Holding AG (RHHBY) Shareholder/Analyst Call Transcript
Roche Highlights Gazyva Progress, Reports Data on Enspryng, MS Drug
RHHBY's Gazyva gets FDA review for lupus as strong trial data and pipeline wins across neurology and MS bolster growth outlook.
Roche submits multiple sclerosis drug fenebrutinib to regulators despite patient deaths
Swiss drugmaker Roche on Wednesday said it was submitting its experimental multiple sclerosis drug fenebrutinib to global regulators after meeting late-stage trial goals while data released on Wednesday showed seven patients died during studies.
The Zacks Analyst Blog Roche Holding, AT&T and Amgen
AMGN, T, and Roche shares outperform as strong drug portfolios and wireless momentum offset key headwinds like pricing pressure and legacy declines.
Roche Halts Development of Drug Candidate for Muscle Diseases, Chugai Says
The company discontinued developing emugrobart after two studies showed the drug didn't achieve intended outcomes.
Roche Bets Splits in Obesity Market Will Open Door to New Entrants
EXCLUSIVE: The pharmaceutical giant is re-entering the obesity market and aims to become a top-three player, rivaling the likes of Eli Lilly and Novo Nordisk.
Roche Vs. Eli Lilly: Nvidia Deals, Obesity Battles Stoke Rivalry (I'd Buy Both)
Roche Holding AG has announced a major AI infrastructure expansion with Nvidia, surpassing peers in GPU deployment for drug development. RHHBY now operates over 3,500 Blackwell GPUs, positioning itself as the pharmaceutical industry leader in AI-driven R&D capabilities. Compared to Eli Lilly and Company, Roche offers stronger value metrics—lower P/E and P/S ratios, higher dividend yield—despite lower profitability.
Strait of Hormuz will partially reopen in 2-3 weeks: David Roche
Quantum Strategy' David Roche says he expects oil reserves can sufficiently support world demand, and that the 'world won't run out of oil'. He also explains why he believes Iran can't afford to escalate the war further, and therefore will not engage militarily on the Strait of Hormuz.
Roche Holding AG (RHHBY) Discusses Phase III Study Results and Updates on Immunology Kidney Pipeline Transcript
Roche Holding AG (RHHBY) Discusses Phase III Study Results and Updates on Immunology Kidney Pipeline Transcript
Roche's Giredestrant Misses Key Goal in First-Line Breast Cancer Study
RHHBY reports that giredestrant plus palbociclib misses the main PFS goal in a phase III first-line breast cancer study, though the combo shows a numerical improvement.
Roche Breast-Cancer Treatment Falls Short of Primary Goal in Late-Stage Study
The combination of Roche's investigational drug, giredestrant, with Pfizer's Ibrance didn't lead to a statistically significant improvement among patients with advanced breast cancer.
